Sukrita Paul brings 13+ years of PV experience across clinical development and post-marketing safety, with particular depth in oncology and complex therapies. Her experience spans established oncology treatments, including chemotherapy and hormonal therapies, through to evolving targeted approaches such as PARP inhibitors, and radioligand therapy.

This combination of therapeutic depth and lifecycle experience informs a practical approach to safety strategy, benefit-risk evaluation, governance and regulatory decision-making.